Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors - A new analysis of data from the archives and implications for improved antimanic treatments

Journal of Psychopharmacology

Volumn 23, Issue 8, 2009, Pages 899-907

  Harrison Read, P E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antimanic potency; Dopamine D2 receptor binding; Improved antimanic drug treatments; Serotonin 5 HT2A receptor binding; Typical neuroleptics

Indexed keywords

BENPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOPENTHIXOL; CLOTIAPINE; DIXYRAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DROPERIDOL; FLUANISONE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OXYPERTINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMAZINE; SEROTONIN 2A RECEPTOR; SULPIRIDE; THIOPROPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPERIDOL; TRIFLUPROMAZINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOPAMINE ANTAGONISTS; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SEROTONIN ANTAGONISTS;

EID: 70449363911     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108094349     Document Type: Article

References (59)

1. Akhondzadeh, S., Mohajari, H., Mohannadi, MR, Amini, H. (2003) Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. BMC Psychiatry 3: 7 ( http://www.biomedcentral.com/1471-244X/3/7 ).
2. Amargos-Bosch, M., Bortolozzi, A., Puig, MV, Serrrats, J., Adell, A., Celada, P., et al. (2004) Co-expression and in vivo interaction of serotonin-1A and serotonin-2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14: 281-299.
3. Bobon, J., Bobon, DP, Pinchard, A., Collard, J., Ban, TA, De Buck, R., et al. (1972 a) A new comparative physiognomy of neuroleptics: a collaborative clinical report. Acta Psychiatr Belg 72: 542-554.
4. Bobon, J., Pinchard, A., Collard, J., Bobon, DP (1972 b) Clinical classification of neuroleptics with special reference to their antimanic, antiautistic and ataraxic properties. Compr Psychiatry 13: 123-131.
5. Carli, M., Baviera, M., Invernizzi, RW, Balducci, C. (2006) Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 31: 757-767.
6. Chouinard, G., Young, SN, Annable, L. (1985) A controlled clinical trial of l-tryptophan in acute mania. Biol Psychiatry 20: 546-557.
7. Cookson, J. (2001) Use of antipsychotic drugs and lithium in mania. Br J Psychiatry 178: s148 - s156.
8. Cookson, J., Silverstone, T., Wells, B. (1981) Double-blind comparative clinical trial of pimozide and clorpromazine in mania: a test of the dopamine hypothesis. Acta Psychiatr Scand 64: 381-397.
9. Coppen, A., Prange Jr, AJ, Whybrow, PC, Noguerra, R., Paez, JM (1969) Methysergide in mania. Lancet 2: 338-340.
10. Court, JH, Mai, FMM (1970) A double-blind intensive crossover design trial of methysergide in mania. Med J Aust 2: 526-529.
11. Cowen, PJ, McCance, SL, Ware, CJ, Cohen, PR, Chalmers, JS, Julier, DL (1991) Lithium in tricyclic-resistant depression: correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 159: 341-346.
12. Deakin, JFW, Graeff, FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol (Oxf) 5: 305-315.
13. Dewhurst, WG (1968 a) A new theory of cerebral amine function and its clinical application. Nature 218: 1130-1133.
14. Dewhurst, WG (1968 b) Methysergide in mania. Nature 219: 506-507.
15. Dewhurst, WG, Marley, E. (1965 a) The effects of alpha-methyl derivatives of noradrenaline, phenylethylamine and tryptamine on the central nervous system of the chicken. Br J Pharmacol 25: 682-704.
16. Dewhurst, WG, Marley, E. (1965 b) Action of sympathomimetic and allied amines on the central nervous system of the chicken. Br J Pharmacol 25: 705-727.
17. Ferrie, L., Young, AH, McQuade, R. (2005) Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. J Psychopharmacol (Oxf) 19: 229-234.
18. Fieve, RR, Platman, SR, Fleiss, JL (1969) A clinical trial of methysergide and lithium in mania. Psychopharmacologia (Berl) 15: 425-429.
19. Gerner, RH, Post, RM, Bunney Jr, WE (1976) A dopaminergic mechanism in mania. Am J Psychiatry 133: 1177-1180.
20. Goodwin, GM (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf) 17: 149-173.
21. Harrison-Read, PE (1983) ĝ€Wet-dog shake behaviour in rats may reflect functionally-opposed indoleamine systems involving different 5-HT receptors. Br J Pharmacol 78: 92P.
22. Harrison-Read, PE (1986) Chronic lithium treatment in rats has different effects on motor responses mediated by 5-HT1 and 5-HT2 receptors. Br J Pharmacol 87: 219P.
23. Haskovec, L., Soucek, K. (1968) Trial of methysergide in mania. Nature 219: 507-508.
24. Hoyer, D., Clarke, DE, Fozard, JR, Hartig, PR, Martin, GR, Mylecharane, EJ, et al. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157-203.
25. Hughes, JH, Dunne, F., Young, AH (2000) Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry 177: 447-451.
26. Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. l, O Laughlin, A., Meltzer, HY (2001) 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 56: 1521-1531.
27. Itil, TM, Polvan, N., Holden, JMC (1971) Clinical and electroencephalographic effects of cinanserin in schizophrenic and manic patients. Dis Nerv Syst 32: 193-200.
28. Jann, MW, Garrelts, JJ, Ereshfsky, L., Saklad, SR (1984) Alternative drug therapies for mania: a literature review. Drug Intell Clin Pharm 18: 577-589.
29. Johnstone, EC, Crow, TJ, Frith, CD, Owens, DCG (1988) The North-wick Park "functional" psychosis study: diagnosis and treatment response. Lancet 2: 119-125.
30. Kane, FJ (1970) Treatment of mania with cinanserin, an antiserotonin agent. Am J Psychiatry 126: 1020-1023.
31. Kapur, S., Remington, G. (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
32. Leysen, JE (1984) Receptors for neuroleptic drugs. Adv Hum Psychopharmacol 3: 315-356.
33. Leysen, JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3: 11-26.
34. Leysen, JE, Janssen, PMF, Schotte, U., Luyten, Whml, Megens, Aahp (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology (Berl) 112: s40 - s54.
35. Leysen, JE, Niemegeers, CJE, Tollenaere, JP, Laduron, PM (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168-171.
36. Leysen, JE, Niemegeers, CJE, Van Nueten, JM, Laduron, PM (1982) Tritiated-ketanserin (R 41 468). a selective tritiated-ligand for serotonin receptor binding sites: binding properties, brain distribution, functional role. Mol Pharmacol 21: 301-314.
37. Marek, GJ, Carpenter, LL, McDougle, CJ, Price, LH (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402-412.
38. Marek, GJ, Martin-Ruiz, R., Abo, A., Artigas, F. (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioural effects of the SSRI fluoxetine. Neuropsychopharmacology 30: 2205-2215.
39. McCabe, MS, Reich, T., Winokur, G. (1970) Methysergide as a treatment for mania. Am J Psychiatry 127: 354-356.
40. Meltzer, HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: s106 - s115.
41. Meltzer, HY, Li, Z., Kaneda, Y., Ichikawa, J. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172.
42. Meltzer, HY, Matsubara, S., Lee, J-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246.
43. Murphy, DL, Baker, M., Goodwin, FK, Miller, H., Kotin, J., Bunney Jr, WE (1974) L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. Psychopharmacologia (Berl) 34: 11-20.
44. Nolen, WA (1983) Dopamine and mania. J Affect Disord 5: 91-96.
45. Ohlsen, RI, Pilowsky, LS (2005) The place of partial agonism in psychiatry: recent developments. J Psychopharmacol (Oxf) 19: 408-413.
46. Peroutka, SJ, Snyder, SH (1979) Multiple serotonin receptors: differential binding of tritiated-5-hydroxytryptamine, tritiated-lysergic acid diethylamide and tritiated-spiroperidol. Mol Pharmacol 16: 687-699.
47. Peroutka, SJ, Snyder, SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518-1522.
48. Post, RM, Jimerson, DC, Bunney, WE, Goodwin, FK (1980) Dopamine and mania: behavioural and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berl) 67: 297-305.
49. Price, LH, Charney, DS, Delgado, PL, Heninger, GR (1990) Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology (Berl) 100: 3-12.
50. Scherk, H., Pajonk, FG, Leucht, S. (2007) Second-generation antipsychotic agents in the treatment of acute mania. A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 64: 442-455.
51. Seeman, P., Tallerico, T., Corbett, R., Van Tol, HHM, Kamboj, RK (1997) Role of dopamine D2, D4 and serotonin 2A receptors in antipsychotic and anticataleptic action. J Psychopharmacol (Oxf) 11: 15-17.
52. Shopsin, B., Georgotas, A., Kane, S. (1979) Psychopharmacology of mania. In: Shopsin, B (ed). Manic Illness. New York: Raven Press, pp. 177-218.
53. Shopsin, B., Gershon, S., Thompson, H., Collins, P. (1975) Psychoactve drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine and haloperidol. Arch Gen Psychiatry 32: 34-42.
54. Siegel, S. (1956) Nonparametric Statistics. Tokyo: McGraw-Hill Kogakusha.
55. Waldmeier, PC (1987) Is there a common denominator for the antimanic effect of lithium and anticonvulsants ? Pharmacopsychiatry 20: 37-47.
56. Weiner, DM, Burnstein, ES, Nash, N., Croston, GE, Currier, EA, Vanover, KE, et al. (2001) 5-hydroxytryptamine 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 229: 268-276.
57. Williams, GV, Rao, SG, Goldman-Rakic, PS (2002) The physiological role of 5-HT2A receptors in working memory. J Neurosci 22: 2843-2854.
58. Wood, AJ, Goodwin, GM (1987) A review of the biochemical and pharmacological actions of lithium. Psychol Med 17: 579-600.
59. Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.